DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
DA Davidson analyst Linda Bolton Weiser maintains a Neutral rating on Medifast (NYSE:MED) and lowers the price target from $67 to $40.
February 21, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DA Davidson maintains a Neutral rating on Medifast and reduces the price target from $67 to $40.
The reduction in price target by DA Davidson suggests a bearish outlook on Medifast's stock, likely due to anticipated underperformance or challenges faced by the company. This could lead to negative investor sentiment and a potential decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100